A UK company is about to start a Phase 1 trial with the drug involving 18 healthy human volunteers and the results are expected to be announced later this year. In an earlier Phase 1 study in nine healthy human volunteers, the treatment was seen to reduce the excretion of sebum by the skin, which is associated with acne development, by up to 70%.
‘The Phase I results are startlingly good,’ said Nigel Blackburn, director of clinical development at the company, Summit, which is organising the trial. ‘Reducing sebum production has been the “holy grail” of acne treatment for 30 years, and there has been little success aside from Roaccutane which has significant side effects.’
The current ‘gold standard’ for acne treatment, Roaccutane can cause a wide range of side effects, including teratogenicity – which leads to abonormalities in the unborn foetus of pregnant women, and has also recently been linked to depression and (inconclusively) to teenage suicides. The market for acne treatments is worth several billion dollars, and any new treatment developed without side effects could potentially reap blockbuster sales.
Although Summit has not disclosed the name of the drug now under evaluation, the company says it represents an entirely new class of compounds for treating acne. ‘At the doses we are looking at any side effects should be mild compared with those resulting from Roaccutane treatment,’ Blackburn commented.
The company hopes to begin critical Phase 2 trials to assess the efficacy of the drug in acne sufferers next year. Depending on the results, the drug could either be formulated as a stand-alone topical treatment or more likely in combination with other existing treatments. The company has already been in talks with several interested companies, who are waiting to see whether the initial results can be repeated in a larger study group.
Lisa Richards | alfa
Team discovers how bacteria exploit a chink in the body's armor
20.01.2017 | University of Illinois at Urbana-Champaign
Rabies viruses reveal wiring in transparent brains
19.01.2017 | Rheinische Friedrich-Wilhelms-Universität Bonn
An important step towards a completely new experimental access to quantum physics has been made at University of Konstanz. The team of scientists headed by...
Yersiniae cause severe intestinal infections. Studies using Yersinia pseudotuberculosis as a model organism aim to elucidate the infection mechanisms of these...
Researchers from the University of Hamburg in Germany, in collaboration with colleagues from the University of Aarhus in Denmark, have synthesized a new superconducting material by growing a few layers of an antiferromagnetic transition-metal chalcogenide on a bismuth-based topological insulator, both being non-superconducting materials.
While superconductivity and magnetism are generally believed to be mutually exclusive, surprisingly, in this new material, superconducting correlations...
Laser-driving of semimetals allows creating novel quasiparticle states within condensed matter systems and switching between different states on ultrafast time scales
Studying properties of fundamental particles in condensed matter systems is a promising approach to quantum field theory. Quasiparticles offer the opportunity...
Among the general public, solar thermal energy is currently associated with dark blue, rectangular collectors on building roofs. Technologies are needed for aesthetically high quality architecture which offer the architect more room for manoeuvre when it comes to low- and plus-energy buildings. With the “ArKol” project, researchers at Fraunhofer ISE together with partners are currently developing two façade collectors for solar thermal energy generation, which permit a high degree of design flexibility: a strip collector for opaque façade sections and a solar thermal blind for transparent sections. The current state of the two developments will be presented at the BAU 2017 trade fair.
As part of the “ArKol – development of architecturally highly integrated façade collectors with heat pipes” project, Fraunhofer ISE together with its partners...
19.01.2017 | Event News
10.01.2017 | Event News
09.01.2017 | Event News
20.01.2017 | Awards Funding
20.01.2017 | Materials Sciences
20.01.2017 | Life Sciences